VUMC scientists ‘sprint’ to find anti-Zika antibodies
January 24, 2019
Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
This is the first of four “scientific sprints” sponsored by the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense, under a five-year cooperative agreement worth up to $28 million that was signed last year.
Therapeutic Promise of a Human Antibody Against West Nile Virus
December 10, 2018
Flaviviruses are single-stranded RNA-containing, enveloped viruses that are primarily transmitted by insects (Figure 1). They include important human pathogens such as dengue virus, Zika virus, yellow fever virus, Japanese encephalitis virus, and west Nile virus (WNV). The most effective means to control these viral illnesses is through the development of vaccines; however, this has only been achieved in the case of yellow fever.
Dr. James Crowe & team identifies highly potent human neutralizing mAb w/ therapeutic potential that targets the West Nile Virus E protein
November 29, 2018
West Nile virus (WNV), a member of the Flavivirus genus, is a leading cause of viral encephalitis in the United States1.
Vanderbilt team uses cancer cells to fight West Nile virus.
November 21, 2018
Researchers at Vanderbilt University Medical Center say they have used cancerous cells to mass produce a human antibody that can be used to “neutralize” West Nile virus, a mosquito-transferred illness that kills about 100 people in the U.S. each year.
Their findings, revealed this week in a research paper published in the scientific journal Nature Microbiology, could lead to the first effective treatment for West Nile, according to a news release.
Nasal gene spray inspired by llama antibodies could prevent all types of flu
November 5, 2018
Four llama antibodies and a harmless virus: This outlandish recipe could be the basis of a nasal spray designed to foil infection from all strains of influenza. The spray, containing a virus engineered to make a protein derived from the llama antibodies, has passed its first animal test, protecting mice from every known flu strain that infects humans, a research team reports.
Llamas may hold the key to a long-lasting flu jab
November 5, 2018
Llamas may hold the key to a long-lasting flu vaccine, research suggests. Laboratory tests showed a protein produced by the fluffy animals, as well as camels, fought off the virus in mice. Rodents were even protected against 60 strains of flu, which cause fever, headache and fatigue in humans, for more than nine months. Currently, flu jabs protect against a maximum of four strains - meaning people can still be struck down by strains that were not predicted to be active. The Belgian study has even raised hopes of a flu nasal spray, after the mice were equally protecte
Crowe Lab Scientists Isolate mAbs That Neutralize GI Virus
September 20, 2018
Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies (mAbs) that can neutralize norovirus, a virus that causes acute gastrointestinal (GI) illness.
Norovirus: Vanderbilt study takes step toward norovirus vaccine, medicinal treatment
September 10, 2018
Norovirus earned its name as the "perfect pathogen"because it spreads faster and farther than most viruses, infecting 20 million people in the United States every year and killing 200,000 worldwide.
Although the virus - the leading cause of gastrointestinal illness - survives typical disinfectants and is constantly changing, researchers at Vanderbilt University have taken a step toward developing a vaccine and toward improving diagnosis and treatment.
USPTO awards Crowe Lab and Vanderbilt an Honorable Mention in 2018's Patents for Humanity Winners
August 22, 2018
The United States Patent and Trademark Office (USPTO) announced the 2018 Patents for Humanity winners with Vanderbilt University awarded an honorable mention.